威尼托克拉克斯和德西塔宾与强化化疗作为新诊断的AML的年轻患者的诱导
Jing Lu1, Shengli Xue2, Ying Wang3
1The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China., Suzhou, China.
Blood
|February 26, 2025
概括
在年轻急性髓性白血病患者中,Venetoclax加上decitabine显示出与标准密集化疗相比的非较低的响应率和改善的安全性. 这种低强度疗法为这个患者群体提供了一个有前途的替代方案.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 与低甲基化剂结合的Venetoclax (VEN) 已被批准用于老年/不适合急性髓性白血病 (AML) 患者.
- 对年轻,未经治疗的AML患者的低强度VEN治疗的前性数据有限.
研究的目的:
- 在年轻,健康,未经治疗的AML患者中,研究VEN加decitabine (VEN-DEC) 与密集化疗 (IA-12) 的疗效和安全性.
- 为了评估VEN-DEC作为一种诱导疗法在这个特定的患者群体.
主要方法:
- 一项随机试验比较VEN-DEC与IA-12 (伊达鲁比和细胞拉宾) 在18-59岁的适合接受强化化疗的患者中.
- 实现复合完全缓解 (CRc) 的患者接受了高剂量的cytarabine巩固.
- 主要终点是诱导后的CRc率.
主要成果:
- 在VEN-DEC中,CRc率为89%,而在IA-12中为79% (非劣质P=.0021).
- 在40岁以上,有不良风险和表观遗传突变的患者中,VEN-DEC显示出优异的CRc,但在RUNX1::RUNX1T1融合病例中CRc较低.
- 较少的等级≥3感染 (32%对67%) 和较短的严重血小板缺血持续时间被观察到与VEN-DEC.
结论:
- 与IA-12相比,VEN-DEC在年轻AML患者中实现了非较低的响应率和更高的安全性.
- 对于部分年轻AML患者来说,VEN-DEC是一种潜在的有效和更安全的诱导策略.
- 需要进一步的随访,以评估长期生存结果.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
09:09Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
8.2K
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Bone Marrow Sampling and Transplants
270
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
270
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
